Weight drives caspofungin pharmacokinetic variability in overweight and obese people: Fractal power signatures beyond two-thirds or three-fourths

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 5, 2013, Pages 2259-2264

  Hall, Ronald G ^a,b   Swancutt, Mark A ^b   Meek, Claudia ^a   Leff, Richard ^a   Gumbo, Tawanda ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; FEMALE; GEOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; ANTHROPOMETRY; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; ECHINOCANDINS; FEMALE; FRACTALS; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; OBESITY;

EID: 84876262274     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01490-12     Document Type: Article

References (36)

1. Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, Sobel JD, Pappas PG, Kullberg BJ. 2012. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin. Infect. Dis. 54:1110-1122.
2. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, Betts R, Wible M, Goldstein BP, Schranz J, Krause DS, Walsh TJ. 2007. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med. 356:2472-2482.
3. Filozof C, Gonzalez C, Sereday M, Mazza C, Braguinsky J. 2001. Obesity prevalence and trends in Latin-American countries. Obes. Rev. 2:99-106.
4. Flegal KM, Carroll MD, Ogden CL, Curtin LR. 2010. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303:235-241.
5. Kruger HS, Puoane T, Senekal M, van der Merwe MT. 2005. Obesity in South Africa: challenges for government and health professionals. Public Health Nutr. 8:491-500.
6. Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML, Gortmaker SL. 2011. The global obesity pandemic: shaped by global drivers and local environments. Lancet 378:804-814.
7. Hope WW, Seibel NL, Schwartz CL, Arrieta A, Flynn P, Shad A, Albano E, Keirns JJ, Buell DN, Gumbo T, Drusano GL, Walsh TJ. 2007. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob. Agents Chemother. 51: 3714-3719.
8. Gumbo T, Hiemenz J, Ma L, Keirns JJ, Buell DN, Drusano GL. 2008. Population pharmacokinetics of micafungin in adult patients. Diagn. Microbiol. Infect. Dis. 60:329-331.
9. Hall RG, Swancutt MA, Gumbo T. 2011. Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people. Antimicrob. Agents Chemother. 55:5107-5112.
10. Wurthwein G, Young C, Lanvers-Kaminsky C, Hempel G, Trame MN, Schwerdtfeger R, Ostermann H, Heinz WJ, Cornely OA, Kolve H, Boos J, Silling G, Groll AH. 2012. Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients. Antimicrob. Agents Chemother. 56:536-543.
11. Jain MK, Pasipanodya JG, Alder L, Lee WM, Gumbo T. 2013. Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection. Antimicrob. Agents Chemother. 57:1115-1120.
12. Hall RG, Swancutt MA, Meek C, Leff RD, Gumbo T. 2012. Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people. Antimicrob. Agents Chemother. 56:1502-1507.
13. D'Argenio DZ, Schumitzky A, Wang X. 2009. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA.
14. Huxley JS, Teissier G. 1936. Terminology of relative growth. Nature 137:780-781.
15. Mandelbrot B. 1967. How long is the coast of Britain? Statistical selfsimilarity and fractional dimension. Science 156:636-638.
16. Andes D, Ambrose PG, Hammel JP, Van Wart SA, Iyer V, Reynolds DK, Buell DN, Kovanda LL, Bhavnani SM. 2011. Use of pharmacokinetic- pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia. Antimicrob. Agents Chemother. 55:2113-2121.
17. West GB, Brown JH, Enquist BJ. 1997. A general model for the origin of allometric scaling laws in biology. Science 276:122-126.
18. West GB, Brown JH, Enquist BJ. 1999. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 284:1677-1679.
19. West GB, Savage VM, Gillooly J, Enquist BJ, Woodruff WH, Brown JH. 2003. Physiology: why does metabolic rate scale with body size? Nature 421:713.
20. Louie A, Deziel M, Liu W, Drusano MF, Gumbo T, Drusano GL. 2005. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob. Agents Chemother. 49:5058-5068.
21. Gumbo T, Drusano GL, Liu W, Kulawy RW, Fregeau C, Hsu V, Louie A. 2007. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob. Agents Chemother. 51:968-974.
22. Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A. 2010. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob. Agents Chemother. 54: 2497-2506.
23. Li CC, Sun P, Dong Y, Bi S, Desai R, Dockendorf MF, Kartsonis NA, Ngai AL, Bradshaw S, Stone JA. 2011. Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients. Antimicrob. Agents Chemother. 55:2098-2105.
24. Ryan DM, Lupinacci RJ, Kartsonis NA. 2011. Efficacy and safety of caspofungin in obese patients. Med. Mycol. 49:748-754.
25. Rubner M. 1883. Ueber den Einfluss der Körpergrösse auf Stoff- und Kraftwechsel. Zeitschr. Biol. 19:535-562.
26. Hoppeler H, Weibel ER. 2005. Scaling functions to body size: theories and facts. J. Exp. Biol. 208:1573-1574.
27. Kleiber M. 1932. Body size and metabolism. Hilgardia 6:315-353.
28. Kleiber M. 1947. Body size and metabolic rate. Physiol. Rev. 27:511-541.
29. Brody S. 1945. Bioenergetics and growth: with special reference to the efficiency complex in domestic animals. Reinhold Publishing Corp, New York.
30. Mandelbrot BB, Evertsz CJ, Hayakawa Y. 1990. Exactly self-similar left-sided multifractal measures. Phys. Rev. A 42:4528-4536.
31. Mandelbrot BB. 1982. The fractal geometry of nature. W. H. Freeman and Company, New York, NY.
32. He JH, Zhang J. 2004. Fifth dimension of life and the 4/5 allometric scaling law for human brain. Cell Biol. Int. 28:809-815.
33. Sharma V, McNeill JH. 2009. To scale or not to scale: the principles of dose extrapolation. Br. J. Pharmacol. 157:907-921.
34. Tang H, Hussain A, Leal M, Fluhler E, Mayersohn M. 2011. Controversy in the allometric application of fixed- versus varying-exponent models: a statistical and mathematical perspective. J. Pharm. Sci. 100:402-410.
35. Mahmood I. 2009. Role of fixed coefficients and exponents in the prediction of human drug clearance: how accurate are the predictions from one or two species? J. Pharm. Sci. 98:2472-2493.
36. Jonsson S, Davidse A, Wilkins J, Van der Walt JS, Simonsson US, Karlsson MO, Smith P, McIlleron H. 2011. Population pharmacokinetics of ethambutol in South African tuberculosis patients. Antimicrob. Agents Chemother. 55:4230-4237.